CIC:	Hospital UPN:	Patient UIC	 HSCT Date:	
				yyyy - mm - dd

## **HSCT - Minimum Essential Data - A**

## **SECOND REPORT - 100 DAYS AFTER HSCT**

Dise	ease
PRIMARY DISEASE DIAGNOSIS	
Centre Ide	entification
EBMT Code (CIC):	Contact person:
Hospital: Unit:	Email:
Patier	nt Data
Date of this report:	
Hospital Unique Patient Number/ Code:  (Compulsory, registrations will not be accepted without this item)  Initials:  (first name(s)	_family name(s))
Date of birth  yyyy - mm - dd	Sex
Date of the transplant:  yyyy - mm - dd	
Reco	overy
Absolute neutrophil count (ANC) recovery (Neutrophils ≥ 0.5 x 10 <sup>9</sup> /containing neutrophils)  No: Date of last assessment:  yyyy - mm - dd  Yes: Date of ANC recovery:	L; first of 3 consecutive values after 7 days without any transfusion
Yes: Date of ANC recovery:	
Platelet reconstitution (Platelets ≥ 20 x 10 %L; first of 3 consecutive No  No  Yes: Date Platelets ≥ 20 x 10 %    Never below this level  Date unknown: patient discharged before levels reached  Date unknown: out-patient  Unknown	e values after 7 days without transfusion)
Early graft loss (Engraftment followed by loss of graft within the fit  No Yes Unknown	rst 100 days)

	Additional Cell Infusions
n	al cell infusions <u>(excluding a new HSCT)</u>
	ui celi ililusions <u>i excuumig u nesi neen j</u>
	Is this cell infusion an allogeneic boost?   No Yes: - Skip Cell therapy table below
	An allo boost is an infusion of cells from the same donor without conditioning, with no evidence of
	graft rejection.
	Is this cell infusion an autologous boost?   No Yes: - Skip Cell therapy table below
ľ	f the cell infusion is <u>not</u> a boost fill in the <b>Cell therapy</b> section below:
	Cell therapy
	First date of the cell therapy infusion
	yyyy - mm - dd
	Source of cell(s): Allo Auto (check all that apply)
	Type of cell(s): (check all that apply)
	☐ Lymphocyte (DLI) ☐ Mesenchymal ☐ Fibroblasts ☐ Dendritic cells
	NK cells Regulatory T-cells Gamma/delta cells Other, specify
	Chronological number of the cell infusion episode for this patient
	Indication: (check all that apply)
	☐ Planned/protocol ☐ Treatment for disease
	☐ Prophylactic ☐ Mixed chimaerism
	☐ Treatment of GvHD ☐ Treatment viral infection
	Loss/decreased chimaerism
	Treatment PTLD, EBV lymphoma
	Other, specify:
	Number of infusions within 10 weeks

Hospital UPN: Patient UIC HSCT Date: yyyy - mm - dd

CIC:

CIC:	Hospital UPN:	Patient UIC	HSCT Date:			
Additional Disease Treatment						
Addition  No Yes:  Date sta	For relapse / progression of yyyy - mm - dd  Chemo/drug No Yes: Imatinib Dasatinil Nilotinib Bortezoi Lenalido Rituxima Velafern Kepivana	(planned before the transplant took place) r persistent disease (not planned)  mesylate (Gleevec, Glivec) o (Sprycel) (Tasigna) mib (Velcade) mide (Revlimid) b (Rituxan, mabthera) min (FGF) se (KGF, palifermin)				
		ug/chemotherapy, specify Ir				
	Best response					
(prior to This field Con CR a	sease status (response) after of any treatment modification in real is not mandatory for Inherited distinued complete remission (CCR) archieved: Date archieved:	esponse to a post HSCT disease assessment,				
Last Contact Date for 100 day Assessment						
If patient	Day 100 assessment :	date of death, otherwise enter Date of HSCT 	T + 100 DAYS APPROX.			

CIC:	Hos	spital UPN:	Patient UIC	HSCT Date:	vvvv - mm - dd		
		F	Relapse/Progression		7,7,7 22		
First Rela	First Relapse or Progression after HSCT (detected by any method						
☐ No:							
Yes:	Date first seen	уууу - mm - dd					
☐ Conti	nuous progression si	nce HSCT					
		Re	elapse of Leukaemias				
	If Yes or Continuous	and diagnosis is acute or	chronic leukaemia, fill in the section	n below:			
	Method of detection of the first relapse or progression after HSCT						
	Fill in only for acute	and chronic leukaem	nias				
	Relapse/progression detected by <u>clinical/haematological</u> method:						
	□ No:	Date assessed					
	☐ Yes:	Date first seen	уууу - mm - dd				
	☐ Not evalua	ted	yyyy mm aa				
	Relapse/progression detected by cytogenetic method:						
	□ No:	Date assessed					
	☐ Yes:	Date first seen	уууу - mm - dd				
	☐ Not evalua	ted	,,,,, aa				
	Relapse/progression detected by <u>molecular</u> method:						
	□ No:	Date assessed					
	☐ Yes:	Date first seen					
	☐ Not evalua	ted	уууу - mm - dd				
Disease assessment at 100 days (All diseases)							
		ient was last seen b date for each method, de	efore day 100 or date of dear epending on the disease)	th			
Was disease	e detected by <u>clinica</u>	ıl/haematological me	thod when the patient was last a	assessed before day 100 or d	ate of death?		
□ No □ Yes							
Last date assessedyyyy - mm - dd							
□ Not evaluated since HSCT was done							

CIC:	Hospital UPN:	Patient UIC		HSCT Date:	yyyy - mm - dd
	Disease A	Assessment at 100			
	l by <u>cytogenetic/FISH</u> meth nd chronic <b>leukaemias</b>	nod when the patient was l	ist assessed before day	100 or date	of death?
☐ No ☐ Yes: W	/as the presence of the dis-	ease considered relapse/pr	ogression since HSCT?	☐ No	Yes:
Last date assesse	ed yyyy - mm - dd				
Not evaluated sin	ce HSCT was done				
	l by <u>molecular</u> method wh nd chroni leukaemias	nen the patient was last ass	essed before day 100 or	date of dea	th?
☐ No ☐ Yes: W	/as the presence of the dis-	ease considered relapse/pr	ogression since HSCT?	☐ No	Yes:
Last date assesse	yyyy - mm - dd				
☐ Not evaluated sin	ce HSCT was done				
	Surviva	al Status at 100 day	's – All diseases		
☐ Relaps ☐ Second ☐ HSCT I ☐ Unknot ☐ Other_	ontributory Cause of Deat  GVHD Interstitial pneumonitis Pulmonary toxicity Infection: bacterial		oriate):		
	viral Fungal parasitic Unknown Rejection/Poor graft funct History of severe Veno occ Haemorrhage Cardiac toxicity Central nervous system (Cl Gastrointestinal (GI) toxicit Skin toxicity Renal failure Multiple organ failure Other, specify	clusive disorder (VOD) NS) toxicity ty			